Medigene AG reports Financial Results and Business Update for Q3 2024 Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...

Medigene AG reports Financial Results and Business Update for Q1 2024 Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...

Medigene Reports Financial Results and Corporate Update for Q3 2023 Focus on executing the strategic plan and delivering shareholder valueFirst MDG2011 pre-clinical data support potential in solid tumor therapyExpansion of patent portfolio and license agreement for...

Medigene AG reports financial results and business update for Q1 2023 Focus on executing the strategic plan and delivering shareholder valueMDG1015 pre-clinical data underline potential in solid tumor therapy Subsequent to Q1, expansion of tools and technologies in our...